Dualitas Therapeutics, founded in 2023, is at the forefront of biotechnology innovation, with a focus on bispecific antibody therapies. The company is driven by its proprietary DualScreen™ discovery engine and aims to address unmet patient needs in immune and inflammatory (I&I) diseases through a promising pipeline, including lead programs DTX-103 and DTX-102. These programs have shown compelling preclinical evidence supporting their potential impact.
The company recently secured a significant $65.00M Series A investment on 01 September 2025, attracting a consortium of esteemed investors such as SV Health Investors, Qiming Venture Partners USA, Versant Ventures, Alexandria Venture Investments, Eli Lilly, and Chugai Venture Fund. Dualitas offers unique partnering opportunities in pioneering bispecific therapies beyond I&I diseases, positioning itself as a promising player in the sector.
